Company intelligence / Profile preview

Agni Bio

San Francisco, CA, USA

Ownership: Private
Development stage: Other

Overview

Agni Bio is a preclinical-stage biotechnology company focused on developing next-generation mitochondrial uncouplers for the treatment of metabolic disorders. The company's platform targets the safe modulation of mitochondrial respiration to increase energy expenditure, offering a potential therapeutic approach for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). By leveraging novel small molecule chemistry, Agni Bio aims to overcome the toxicity challenges historically associated with mitochondrial uncoupling agents like DNP. The company was part of the Y Combinator Winter 2021 cohort and is headquartered in San Francisco.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

AGB201

Preclinical

Beyond the preview

Go deeper on Agni Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agni Bio.

Explore the full profile